Hospital
Saint Clare Hospital
Saint Clare Hospital was paid $30.09M by Medicaid between Jan 2018 and Dec 2024, across 294 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 18% of everything it billed.
33Billing provider infoSAINT CLARE HOSPITAL
LAKEWOOD, WA 98499
LAKEWOOD, WA 98499
33aNPI1689672693assigned 07/13/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.09M
24GClaims1,144,093
24DCodes billed294
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#21 of 49
Median peer was paid$20.06M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 215,841 | $5.73M | |
| 2019 | 203,443 | $5.45M | |
| 2020 | 159,593 | $4.32M | |
| 2021 | 159,565 | $4.00M | |
| 2022 | 153,974 | $4.19M | |
| 2023 | 143,515 | $3.56M | |
| 2024incomplete | 108,162 | $2.84M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 18,249 | 15,095 | $5.41M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 37,433 | 35,032 | $3.81M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 38,755 | 35,528 | $3.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 24,477 | 22,227 | $1.98M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.0% | 9,234 | 8,857 | $1.52M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 13,859 | 13,092 | $1.28M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 9,276 | 8,743 | $1.19M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 3.1% | 4,453 | 3,116 | $943K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.9% | 9,518 | 7,873 | $868K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 13,360 | 7,735 | $692K |
| 95806 | 2.1% | 1,631 | 1,610 | $621K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 5,587 | 5,066 | $601K |
282 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 3,110 | $482K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 15,840 | $431K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 2,788 | $414K |
| 96415 | 1.4% | 1,622 | $411K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 17,149 | $388K |
| 64493 | 1.1% | 667 | $337K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,784 | $337K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,101 | $249K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,829 | $216K |
| 76830 | Ultrasound, transvaginal | <1% | 2,570 | $211K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,079 | $186K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 476 | $173K |
| 12001 | <1% | 769 | $157K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 35,359 | $151K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,440 | $145K |
| 70496 | <1% | 895 | $140K | |
| 95811 | <1% | 444 | $136K | |
| 84484 | <1% | 28,964 | $135K | |
| 97161 | <1% | 3,267 | $129K | |
| 80053 | Comprehensive metabolic panel | <1% | 27,390 | $128K |
| G0378 | Hospital observation service, per hour | <1% | 5,039 | $125K |
| 93971 | <1% | 1,435 | $121K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,647 | $113K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 549 | $112K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,116 | $100K |
| 10060 | <1% | 507 | $94K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 67 | $92K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,326 | $90K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12,525 | $84K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,291 | $81K |
| 29125 | <1% | 392 | $79K | |
| 87040 | <1% | 10,151 | $76K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 174 | $67K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,882 | $67K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 504 | $61K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,285 | $58K |
| 83605 | <1% | 10,679 | $57K | |
| 76536 | <1% | 723 | $57K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,197 | $56K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,077 | $54K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,505 | $53K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 80 | $53K |
| 76770 | <1% | 563 | $46K | |
| 72100 | <1% | 3,418 | $45K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,687 | $44K |
| 90715 | <1% | 2,505 | $43K | |
| 80076 | <1% | 17,807 | $43K | |
| 80047 | <1% | 6,269 | $42K | |
| 84145 | <1% | 3,879 | $41K | |
| 96367 | <1% | 987 | $39K | |
| 64483 | <1% | 96 | $39K | |
| 85379 | <1% | 6,810 | $38K | |
| 93970 | <1% | 488 | $37K | |
| 71250 | <1% | 807 | $35K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,936 | $35K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 29 | $35K |
| 97162 | <1% | 856 | $33K | |
| 70486 | <1% | 1,073 | $33K | |
| 70498 | <1% | 908 | $31K | |
| 83880 | <1% | 6,907 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 31,698 | $29K |
| 64635 | <1% | 51 | $29K | |
| 73562 | <1% | 1,591 | $27K | |
| 76801 | <1% | 750 | $26K | |
| 70491 | <1% | 230 | $25K | |
| 72040 | <1% | 1,529 | $24K | |
| 73630 | <1% | 3,242 | $23K | |
| 73130 | <1% | 3,386 | $23K | |
| 12002 | <1% | 109 | $22K | |
| 93017 | <1% | 234 | $22K | |
| 73030 | <1% | 2,927 | $21K | |
| 97113 | <1% | 522 | $21K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 66,810 | $20K |
| 97116 | <1% | 1,578 | $18K | |
| 74018 | <1% | 1,728 | $18K | |
| 73502 | <1% | 2,230 | $18K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 119 | $17K |
| 76870 | <1% | 183 | $16K | |
| 12011 | <1% | 80 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,991 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 26,624 | $13K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 67 | $12K |
| 73700 | <1% | 190 | $12K | |
| 97166 | <1% | 287 | $12K | |
| 49083 | <1% | 30 | $11K | |
| 80143 | <1% | 3,059 | $11K | |
| 87641 | <1% | 1,117 | $10K | |
| 73560 | <1% | 2,634 | $10K | |
| 97165 | <1% | 302 | $10K | |
| 73610 | <1% | 2,343 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,934 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,018 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,127 | $7K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 106 | $7K |
| 73110 | <1% | 1,421 | $6K | |
| 82553 | <1% | 1,132 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,056 | $6K |
| 80179 | <1% | 2,871 | $6K | |
| 64490 | <1% | 17 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 268 | $6K |
| 83735 | <1% | 8,686 | $5K | |
| 72202 | <1% | 179 | $5K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 350 | $5K |
| 76882 | <1% | 62 | $5K | |
| 76942 | <1% | 179 | $5K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 96 | $5K |
| 73120 | <1% | 233 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,165 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,663 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,959 | $4K |
| 82962 | <1% | 13,833 | $4K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 35 | $4K |
| 84702 | <1% | 9,261 | $4K | |
| 85610 | <1% | 27,631 | $4K | |
| 83690 | <1% | 21,994 | $4K | |
| 72141 | <1% | 29 | $4K | |
| 72070 | <1% | 380 | $4K | |
| 81001 | <1% | 23,969 | $4K | |
| 73221 | <1% | 27 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,119 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,505 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 15 | $3K |
| 71271 | <1% | 37 | $3K | |
| 10061 | <1% | 17 | $3K | |
| 84703 | <1% | 7,770 | $3K | |
| 73140 | <1% | 337 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,891 | $2K |
| 76937 | <1% | 26 | $2K | |
| 64494 | <1% | 623 | $2K | |
| 73620 | <1% | 185 | $2K | |
| 90686 | <1% | 185 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 673 | $2K |
| 84100 | <1% | 5,175 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,470 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 12,336 | $2K |
| 73070 | <1% | 510 | $2K | |
| 73590 | <1% | 725 | $1K | |
| 82550 | <1% | 3,142 | $1K | |
| 87205 | <1% | 4,155 | $1K | |
| 87070 | <1% | 4,085 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,208 | $1K |
| 81025 | <1% | 5,822 | $1K | |
| 86900 | <1% | 2,296 | $1K | |
| 82565 | <1% | 2,669 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,534 | $1K |
| 81003 | <1% | 10,523 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 14 | $1K |
| 74022 | <1% | 664 | $1K | |
| 74270 | <1% | 12 | $967.94 | |
| 82330 | <1% | 2,912 | $940.70 | |
| 86140 | <1% | 1,444 | $928.39 | |
| 86850 | <1% | 1,559 | $886.41 | |
| 97163 | <1% | 25 | $866.50 | |
| 87430 | <1% | 3,061 | $843.64 | |
| 87808 | <1% | 2,824 | $756.54 | |
| 64636 | <1% | 52 | $627.20 | |
| 73090 | <1% | 293 | $599.03 | |
| 80061 | Lipid panel | <1% | 204 | $596.06 |
| 86901 | <1% | 2,435 | $591.91 | |
| 80051 | <1% | 1,662 | $579.99 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 786 | $564.45 |
| G0008 | Administration of influenza virus vaccine | <1% | 184 | $560.51 |
| 87186 | <1% | 3,815 | $521.35 | |
| J3490 | Unclassified drugs | <1% | 258 | $483.14 |
| 85014 | <1% | 551 | $481.15 | |
| 82075 | <1% | 685 | $477.71 | |
| 80050 | General health panel | <1% | 86 | $436.97 |
| J2704 | Injection, propofol, 10 mg | <1% | 5,775 | $435.37 |
| 85651 | <1% | 1,458 | $427.88 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,814 | $388.80 |
| 82803 | <1% | 1,558 | $382.30 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,620 | $369.88 |
| 85730 | <1% | 4,005 | $368.13 | |
| 96376 | <1% | 7,400 | $343.08 | |
| 87077 | <1% | 1,930 | $335.49 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,877 | $322.85 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,575 | $315.95 |
| 64447 | <1% | 12 | $309.08 | |
| 74019 | <1% | 126 | $306.04 | |
| C1729 | Catheter, drainage | <1% | 134 | $305.38 |
| 96368 | <1% | 27 | $290.30 | |
| 71101 | <1% | 154 | $285.42 | |
| 86923 | <1% | 22 | $280.17 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,327 | $276.29 |
| 72131 | <1% | 14 | $257.97 | |
| 0240U | <1% | 2,024 | $229.74 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 142 | $226.95 |
| 51798 | <1% | 58 | $186.11 | |
| 85027 | <1% | 254 | $182.04 | |
| 51702 | <1% | 67 | $178.84 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,757 | $156.26 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,729 | $153.28 |
| 88304 | <1% | 1,018 | $147.94 | |
| 72072 | <1% | 12 | $147.07 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,388 | $141.82 |
| 82947 | <1% | 1,518 | $135.94 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 137 | $94.63 |
| A9270 | Non-covered item or service | <1% | 20,942 | $91.35 |
| 73552 | <1% | 27 | $85.50 | |
| 73600 | <1% | 12 | $84.67 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,101 | $78.87 |
| 85018 | <1% | 222 | $69.83 | |
| 87147 | <1% | 504 | $69.77 | |
| 82728 | <1% | 41 | $66.84 | |
| 84132 | <1% | 195 | $66.31 | |
| 82607 | <1% | 48 | $64.87 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,773 | $63.84 |
| 83540 | <1% | 99 | $63.12 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,411 | $61.69 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 518 | $58.25 |
| 82140 | <1% | 134 | $54.21 | |
| 82010 | <1% | 211 | $53.59 | |
| 36600 | <1% | 485 | $52.11 | |
| 83550 | <1% | 85 | $46.41 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,787 | $43.66 |
| 73060 | <1% | 12 | $41.23 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,911 | $40.46 |
| 85049 | <1% | 85 | $33.54 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,180 | $30.02 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,282 | $27.07 |
| 87807 | <1% | 124 | $26.46 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 847 | $24.61 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 39 | $24.30 |
| 82248 | <1% | 27 | $24.27 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,393 | $22.47 |
| 82150 | <1% | 251 | $21.54 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 863 | $19.25 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 964 | $13.49 |
| 0352U | <1% | 262 | $13.09 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,974 | $12.96 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,711 | $10.76 |
| 82746 | <1% | 15 | $8.43 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 342 | $7.04 |
| 99152 | <1% | 79 | $6.11 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 481 | $5.53 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,373 | $3.54 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 289 | $1.65 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,079 | $1.52 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 983 | $1.12 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 1,955 | $0.51 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 593 | $0.36 |
| C1769 | Guide wire | <1% | 398 | $0.28 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,016 | $0.21 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,390 | $0.05 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 76 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 86 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 37 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 90 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 63 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 314 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 291 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 139 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 245 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 70 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 14 | $0.00 |
| 64491 | 0% | 16 | $0.00 | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 66 | $0.00 |
| 89051 | 0% | 25 | $0.00 | |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 29 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 16 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 77 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 40 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 14 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 174 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 261 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,823 | $0.00 |
| 87428 | 0% | 56 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 87 | $0.00 |
| 88307 | 0% | 43 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 626 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 550 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 38 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 47 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 314 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 114 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 20 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 126 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 138 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 45 | $0.00 |
| 0099U | 0% | 17 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFITZGERALD, MIKE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Enumclaw Regional Hospital Association | Enumclaw, WA | $23.15M |
| FHS Inpatient Team | Tacoma, WA | $323K |
| FHS Inpatient Team | Lakewood, WA | $301K |
| FHS Inpatient Team | Federal Way, WA | $181K |
| Franciscan Health System | Tacoma, WA | $85K |
| United States Catholic Conference | Federal Way, WA | $43K |
| FHS Inpatient Team | Gig Harbor, WA | $27K |
| Franciscan Medical Group | Silverdale, WA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.